zithromax and Stomatitis

Topics: Adolescent; Azithromycin; Child; Conjunctivitis; Fluid Therapy; Humans; Lidocaine; Male; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Stevens-Johnson Syndrome; Stomatitis; Urethritis

This study aimed to investigate the effects of azithromycin suspension on oral mucositis in patients undergoing hematopoietic stem cell transplantation (HSCT).. The study was designed as a single-blind randomized controlled trial in Taleghani medical center affiliated to Shahid Beheshti University of Medical Sciences Tehran Iran. Patients undergoing HSCT were randomly assigned to intervention or control groups. Azithromycin suspension was administered twice daily by gargling for 30 s and swallowing, on the first day of chemotherapy for patients in the intervention group. Graded oral mucositis (OM) occurrence based on National Cancer Institute Common Toxicity Criteria (NCI-CTC) scale (grade 0 to 5) was considered the main outcome, and the Numerical Rating Scale (NRS:0-10) measured the severity of OM symptoms.. In a duration of 15 months, 88 patients were randomly assigned and finally 70 patients were evaluable for study outcomes (randomized 1:1 to azithromycin versus no-azithromycin). The incidence and duration of the mucositis significantly improved in the intervention group compared to the control. Azithromycin use was consistent with a lower rate of dryness (P < 0.001), dysphagia (P < 0.001), and loss of sense of taste (P < 0.001). Also, in the intervention group, lower intensity of pain due to mucositis (P = 0.01) and lower duration of mucositis were observed (p = 0.045). No significant adverse drug reaction was observed in patients receiving azithromycin.. Based on the result from this study, azithromycin suspension is an effective option in the prevention and treatment of chemotherapy-induced OM. Further study is needed to assess the effect of azithromycin and comparison with other therapeutic options.. Iranian Registry of Clinical Trials: IRCT201603093210N13.

Topics: Azithromycin; Hematopoietic Stem Cell Transplantation; Humans; Iran; Single-Blind Method; Stomatitis

This RCT compared non-surgical treatment of peri-implant mucositis with or without systemic antibiotics.. Forty-eight subjects received non-surgical debridement with or without systemic Azithromax (®) (4 days), and were followed during 6 months. The checkerboard DNA-DNA hybridization method was used to analyse the microbiological material.. Five subjects were excluded due to antibiotic medication during follow-up. At baseline,1 and 3 months no group differences were found. Statistical analysis failed to demonstrate differences in probing pocket depths (PPD) values at 6 months (Mean diff PPD: 0.5 mm, SE: ±0.4 mm, 95% CI: -0.2, 1.3, p = 0.16). Mean% implant bleeding decreased between baseline and month 6 from 82.6% to 27.3% in the test, and from 80.0% to 47.5% in the control group (p < 0.02). Throughout the study, no study group differences in bacterial counts were found.. No short-term differences were found between study groups. The clinical improvements observed at 6 months may be attributed to improvements in oral hygiene. The present study does not provide evidence for the use of systemic antibiotics in treatment of peri-implant mucositis.

Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Bacteroides; Campylobacter; Combined Modality Therapy; Dental Implantation, Endosseous; Dental Implants; DNA, Bacterial; Fusobacterium nucleatum; Humans; Linear Models; Middle Aged; Mucositis; Peri-Implantitis; Periodontal Debridement; Periodontal Index; Single-Blind Method; Statistics, Nonparametric; Stomatitis; Treatment Outcome

Topics: Adult; Azithromycin; Ceftriaxone; Chlamydophila Infections; Chlamydophila pneumoniae; Community-Acquired Infections; Dexamethasone; Female; Humans; Pneumonia, Bacterial; Stomatitis

Topics: Adult; Agglutination Tests; Anti-Bacterial Agents; Azithromycin; Diagnosis, Differential; Female; Humans; Infusions, Intravenous; Mucositis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Stevens-Johnson Syndrome; Stomatitis; Treatment Outcome

Treatment of malignancy with anti-programmed cell death 1 (PD-1) immune checkpoint inhibitors can cause mucocutaneous side effects resulting from T cell activation. Due to their recent development, the full side effect profile remains to be fully elucidated, however dermatologic adverse events are most common. The main oral toxicities of these immune checkpoint inhibitors include: xerostomia, dysgeusia, and lichenoid reactions. Oral mucositis occurs more rarely in the setting of PD-1 inhibition, and few other reports of a Grade 3 or higher, severe, stomatitis have been reported in the literature. We present a case of a 78-year-old woman with Grade 3 ulcerative oral mucositis that occurred 13 months after initiation of PD-1 inhibitor, pembrolizumab, for the treatment for lung adenocarcinoma. She was successfully treated with prednisone, and pembrolizumab was temporarily held by her oncologist. Physicians should be aware of the possibility of severe mucositis in the setting of PD-1 inhibitors, as well as the management. J Drugs Dermatol. 2018;17(7):807-809.

Topics: Adenocarcinoma; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Azithromycin; Female; Humans; Lung Neoplasms; Melanoma; Programmed Cell Death 1 Receptor; Severity of Illness Index; Stomatitis

Topics: Analgesics; Anti-Bacterial Agents; Azithromycin; Balanitis; Ceftriaxone; Child; Combined Modality Therapy; Conjunctivitis; Diagnosis, Differential; Drug Therapy, Combination; Germany; Hemagglutination Tests; Humans; Male; Parenteral Nutrition, Total; Pneumonia, Mycoplasma; Stomatitis